New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Skip to main content
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptides / Dulaglutide

FDA and NIH data · updated 2026-10-16

Dulaglutide: FDA status and clinical evidence

FDA-approved

Dulaglutide is approved by the FDA and is on the US market, first approved September 18, 2014, under 1 application. 142 studies are registered on ClinicalTrials.gov, reaching Phase 4.

Yes
FDA-approved
142
Registered studies
Phase 4
Highest phase
1
FDA applications

FDA approval status

Status
Approved
First approval
September 18, 2014
Most recent approval
September 18, 2014
Applications on file
1
Brand names
TRULICITY
Sponsors
ELI LILLY AND CO
Routes
INJECTION
Dosage forms
INJECTABLE
Marketing status
Prescription
Priority review
Yes

FDA review documents

Clinical evidence

Registered studies
142
Interventional
117
Completed
88
Currently active
23
Studies with posted results
61
Highest phase reached
Phase 4
Total enrolment across studies
26,908,175

By phase

Phase 336
Phase 228
Phase 425
Phase 124
Not applicable8

Full trial breakdown for Dulaglutide →

Molecular identity

Substance class
Protein
FDA UNII
WTT295HSY5
CAS number
923950-08-7
WHO ATC code
Sequence length
275 residues
Molecular weight
59700 g/mol
Recorded synonyms
12

From the FDA Global Substance Registration System, the registry that assigns every substance the FDA tracks a unique identifier.

How to read this. This page reports what federal records say about Dulaglutide, nothing more. An FDA approval covers specific uses and doses on a reviewed label. A registered trial records that research was declared, not that it succeeded. A listed patent governs who may sell a drug, not whether it works. None of this is medical advice, and none of it means a compound is safe to use outside a prescription.

Frequently asked questions

Is Dulaglutide FDA-approved?

Yes. Dulaglutide holds FDA approval and is marketed in the US. Approval covers the specific uses, doses and forms on the FDA label, not every use it is sold or discussed for.

How much clinical research is there on Dulaglutide?

142 studies are registered on ClinicalTrials.gov with Dulaglutide as an intervention, 88 of them completed. The highest phase reached is Phase 4. Registration counts research activity, not proven benefit.

What brand names is Dulaglutide sold under?

FDA records list TRULICITY. Brand availability changes over time, and some applications on file are marked discontinued.

Where does the information on this page come from?

Four FDA and NIH sources: Drugs@FDA for approval records, the FDA Orange Book for patents and exclusivity, the FDA Global Substance Registration System for molecular identity, and ClinicalTrials.gov for trial counts. Each is refreshed on a schedule and the date above shows the last refresh.

Sources: Drugs@FDA, FDA Orange Book, FDA Global Substance Registration System and ClinicalTrials.gov. Last refreshed 2026-10-16.